MISTRG mice have been developed, from 2005 to 2014, in a collaborative effort between the labs of Pr. Richard A. Flavell (Yale University), Pr. Markus G. Manz (University of Zürich) and Regeneron Pharmaceuticals, with funding from the Bill and Melinda Gates Foundation.
MISTRG are used for the efficient generation of "humanized mice", i.e. mice repopulated with a human immune system.
MISTRG are highly immunodeficient mice that lack T and B lymphocytes and NK cells, preventing immun erejection of the human graft. They express the human SIRPa protein, a "don't-eat-me" signal, that protects human cells from phagocytosis. Finally, several cytokine-encoding genes are humanized by knock-in replacement, resulting in defects in mouse cell populations and support for human cells. These cytokines are M-CSF, IL-3, GM-CSF and Thrombopoietin.
MISTRG is an acronym for the 7 modified genes in the genome of these mice: M-CSFh/h IL-3/GM-CSFh/h SIRPah/h TPOh/h RAG2-/- IL2Rg-/-
Feel free email us, we will be happy to share our lab protocols.
Development and function of human innate immune cells in a humanized mouse model. A. Rongvaux, Tim Willinger, J. Martinek, T. Strowig, S.V. Gearty, L.L. Teichmann, Y. Saito, F. Marches, S. Halene, A.K. Palucka, M.G. Manz, R.A. Flavell. 2014. Nature Biotechnology. 32(4):364-72.
News and Views by: H. Spits. New models of human immunity. Nature Biotechnology. 32:335-6.
The MISTRG group at Yale University in 2010 - Cagan Gurer (Regeneron Pharmaceuticals), Markus Manz (University of Zürich), Anthony Rongvaux, Chiara Borsotti, Jenny (Bill & Melinda Gates Foundation), Richard Flavell, Elizabeth Eynon, William Philbrick, Chozhavendan Rathinam, Till Strowig, Tim Willinger, Rouven Müller and Hitoshi Takizawa.